In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.14 below Turn Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 339 other companies have achieved higher Quick Ratio than Turn Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1186 to 1858.

Explain Quick Ratio?
How much Cash & cash equivalents TTRX�s has?
What are TTRX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TTRX Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Dec 31 2024) Q2
Y / Y Current Liabilities Change	1213.37 %	-	-	-	-
Y / Y Cash & cash equivalent Change	1864.4 %	-	-	-	-
Quick Ratio MRQ	1.14	2.19	0.85	1.35	0.76
TTRX's Total Ranking	# 1858	# 1186	# 1962	# 0	#
Seq. Current Liabilities Change	70.82 %	-14.54 %	159.97 %	246.07 %	-
Seq. Cash & cash equivalent Change	-11.3 %	120.78 %	63.25 %	514.47 %	-

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 340
Healthcare Sector	# 606
Overall Market	# 1858

Quick Ratio Statistics
High	Average	Low
2.19	1.26	0.76
(Mar 31 2026)		(Dec 31 2024)

Financial Statements
Turn Therapeutics Inc 's Current Liabilities	$ 9 Millions	Visit TTRX's Balance sheet
Turn Therapeutics Inc 's Cash & cash equivalent	$ 10 Millions	Visit TTRX's Balance sheet
Source of TTRX's Sales		Visit TTRX's Sales by Geography

Cumulative Turn Therapeutics Inc 's Quick Ratio

TTRX's Quick Ratio for the trailling 12 Months

TTRX Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	3227.94 %	-	-	-	-
Y / Y Cash & cash equivalent TTM Growth	5696.66 %	-	-	-	-
Quick Ratio TTM	1.32	1.41	0.97	1.22	0.76
Total Ranking TTM	#	#	#	#	#
Seq. Current Liabilities TTM Growth	57.38 %	57.13 %	201.69 %	346.07 %	-
Seq. Cash & cash equivalent TTM Growth	47.41 %	128.94 %	140.4 %	614.47 %	-

Quick ratio ranking by company, industry and sector >> Back to TTRX Financial Strength Comparisons >> Go to Compare TTRX Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q2 2026 to $8.76 millions, cumulative Quick Ratio decreased to 1.32 above the TTRX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 339 other companies have achieved higher Quick Ratio than Turn Therapeutics Inc . While overall ranking is unchanged compared to the previous 12 months at no. 0.

Explain Quick Ratio?
How much Cash & cash equivalents TTRX�s has?
What are TTRX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 340
Healthcare Sector	# 606
Within the Market	# 1858

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.19	1.26	0.76
(Mar 31 2026)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Tg Therapeutics Inc	3.02	$ 811.665 Millions	$ 268.493 Millions
Dermata Therapeutics Inc	3.02	$ 4.413 Millions	$ 1.462 Millions
Xilio Therapeutics Inc	2.99	$ 136.040 Millions	$ 45.487 Millions
Cadrenal Therapeutics Inc	2.99	$ 4.476 Millions	$ 1.497 Millions
Zevra Therapeutics Inc	2.99	$ 145.321 Millions	$ 48.632 Millions
Inhibitor Therapeutics Inc	2.95	$ 0.516 Millions	$ 0.175 Millions
Annovis Bio Inc	2.95	$ 18.736 Millions	$ 6.359 Millions
Puma Biotechnology Inc	2.89	$ 144.164 Millions	$ 49.825 Millions
Ptc Therapeutics inc	2.89	$ 2,229.082 Millions	$ 771.068 Millions
Werewolf Therapeutics Inc	2.80	$ 21.987 Millions	$ 7.863 Millions
Alzamend Neuro Inc	2.77	$ 7.591 Millions	$ 2.739 Millions
Scienture Holdings Inc	2.71	$ 8.188 Millions	$ 3.026 Millions
Acadia Pharmaceuticals Inc	2.65	$ 956.474 Millions	$ 361.436 Millions
Edesa Biotech Inc	2.63	$ 10.300 Millions	$ 3.910 Millions
Hepion Pharmaceuticals Inc	2.63	$ 1.629 Millions	$ 0.620 Millions
Stoke Therapeutics Inc	2.62	$ 110.004 Millions	$ 41.930 Millions
Elicio Therapeutics Inc	2.55	$ 23.480 Millions	$ 9.202 Millions
Adc Therapeutics Sa	2.54	$ 219.107 Millions	$ 86.332 Millions
Beone Medicines Ltd	2.50	$ 5,290.368 Millions	$ 2,119.187 Millions
Ironwood Pharmaceuticals inc	2.41	$ 79.127 Millions	$ 32.854 Millions
Schrodinger Inc	2.38	$ 413.739 Millions	$ 173.845 Millions
Insmed Inc	2.37	$ 1,160.312 Millions	$ 490.508 Millions
Biovie Inc	2.37	$ 8.977 Millions	$ 3.796 Millions
Tao Synergies Inc	2.30	$ 2.368 Millions	$ 1.032 Millions
Madrigal Pharmaceuticals Inc	2.24	$ 839.419 Millions	$ 374.204 Millions
Rockwell Medical inc	2.23	$ 24.936 Millions	$ 11.174 Millions
Ars Pharmaceuticals Inc	2.22	$ 143.845 Millions	$ 64.728 Millions
Alnylam Pharmaceuticals Inc	2.19	$ 3,308.147 Millions	$ 1,512.513 Millions
Xeris Biopharma Holdings Inc	2.16	$ 243.494 Millions	$ 112.826 Millions
Ardelyx inc	2.13	$ 281.830 Millions	$ 132.220 Millions

Date modified: 2026-09-08T22:38:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.